Item 3.    LEGAL PROCEEDINGS
The information called for by this item is incorporated herein by reference to the information set forth in Note 15 “Legal Proceedings” of the Notes to Consolidated Financial Statements included in Item 8 of this Report.
Item 4.    MINE SAFETY DISCLOSURES
None.
-69-
Table of Contents
PART II
Item 5.    MARKET FOR THE REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS, AND ISSUER PURCHASES OF EQUITY SECURITIES
Market for Our Common Stock
Our common stock has been traded on the NASDAQ Global Market under the symbol "FOLD" since May 31, 2007. Prior to that time, there was no public market for our common stock. The closing price for our common stock as reported by the NASDAQ Global Market on February 10, 2025 was 
$9.64
 per share. As of February 10, 2025, there were 14 holders of record of our common stock.
Dividends
We have never declared or paid any dividends on our capital stock. We currently intend to retain any future earnings to finance the development and growth of our business. We do not intend to declare or pay cash dividends to our stockholders in the foreseeable future.
Recent Sales of Unregistered Securities
None.
-70-
Table of Contents
Performance Graph
The following performance graph compares the cumulative total return on our common stock during the last five fiscal years with the NASDAQ Composite Index (U.S.) and the NASDAQ Biotechnology Index during the same period. The graph shows the value at the end of each of the last five fiscal years of $100 invested in our common stock. Pursuant to applicable SEC rules, all values assume reinvestment of the full amount of all dividends, however no dividends have been declared on our common stock to date. The stockholder return shown on the graph below is not necessarily indicative of future performance, and we do not make or endorse any predictions as to future stockholder returns.
12/31/2019
12/31/2020
12/31/2021
12/31/2022
12/31/2023
12/31/2024
Amicus Therapeutics, Inc.
$100
$237
$119
$122
$146
$97
NASDAQ Composite
$100
$144
$174
$116
$165
$215
NASDAQ Biotechnology
$100
$126
$125
$110
$118
$114
The stock price performance included in this graph is not necessarily indicative of future stock price performance.
Issuer Purchases of Equity Securities
The following table provides certain information with respect to purchase of our common stock during the three months ended December 31, 2024:
Period
Total Number of Shares Purchased 
(1)
Average Price Paid per Share
Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs
Maximum Number (or Approximate Dollar Value) of Shares That May Yet Be Purchased Under the Plans or Programs
October 1, 2024 through October 31, 2024
39,319 
$
10.38 
— 
— 
November 1, 2024 through November 30, 2024
20,565 
$
10.62 
— 
— 
December 1, 2024 through December 31, 2024
20,447 
$
9.36 
— 
— 
Total
80,331 
$
10.18 
— 
— 
______________________________
(1)
 Represents shares of common stock withheld to satisfy taxes associated with the vesting of restricted stock awards.
Item 6.    [RESERVED]
-71-
Table of Contents